1-[2-[4-[[2-(4-Methylsulfonylphenyl)-6-phenylmethoxy-1-benzothiophen-3-yl]oxy]phenoxy]ethyl]piperidine | 648906-08-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2-[4-[[2-(4-Methylsulfonylphenyl)-6-phenylmethoxy-1-benzothiophen-3-yl]oxy]phenoxy]ethyl]piperidine
• CAS: 648906-08-5
• 化学式: C₃₅H₃₅NO₅S₂
• 分子量: 613.799
• InChiKey: YMHXCBCDIKOWCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  43
• 可旋转键数：
  11
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-[2-[4-[[2-(4-Methylsulfonylphenyl)-6-phenylmethoxy-1-benzothiophen-3-yl]oxy]phenoxy]ethyl]piperidine 在 palladium dihydroxide 甲酸铵 作用下， 生成 2-(4-methanesulfonyl-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thiophen-6-ol
  参考文献：
  名称：

  Structure–activity relationships of SERMs optimized for uterine antagonism and ovarian safety

  摘要：

  Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.044
• 作为产物：
  描述：

  6-甲氧基苯并噻吩 在 palladium diacetate 氢氧化钾 、 titanium(III) chloride 、 potassium tert-butylate 、 双氧水 、 溴 、 sodium hydride 、 cesium fluoride 、 三氟乙酸 、 三环己基膦 、 乙硫醇钠 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 为溶剂， 生成 1-[2-[4-[[2-(4-Methylsulfonylphenyl)-6-phenylmethoxy-1-benzothiophen-3-yl]oxy]phenoxy]ethyl]piperidine
  参考文献：
  名称：

  Structure–activity relationships of SERMs optimized for uterine antagonism and ovarian safety

  摘要：

  Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.044

文献信息

• Selective estrogen receptor modulators containing a phenylsulfonyl group
  申请人：Eli Lilly & Company

  公开号：EP1782810A2

  公开（公告）日：2007-05-09

  The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

  本发明涉及一种式 I 的选择性雌激素受体调节剂： 或其药用酸加成盐；可用于治疗子宫内膜异位症和/或子宫白肌瘤/卵巢白肌瘤。
• Structure–activity relationships of SERMs optimized for uterine antagonism and ovarian safety
  作者：Timothy I. Richardson、Scott A. Frank、Minmin Wang、Christian A. Clarke、Scott A. Jones、Bai-Ping Ying、Dan T. Kohlman、Owen B. Wallace、Timothy A. Shepherd、Robert D. Dally、Alan D. Palkowitz、Andrew G. Geiser、Henry U. Bryant、Judith W. Henck、Ilene R. Cohen、Daniel G. Rudmann、Denis J. McCann、David E. Coutant、Samuel W. Oldham、Conrad W. Hummel、Kin C. Fong、Ronald Hinklin、George Lewis、Hongqi Tian、Jeffrey A. Dodge

  DOI：10.1016/j.bmcl.2007.04.044

  日期：2007.7

  Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation. (c) 2007 Elsevier Ltd. All rights reserved.